Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 38

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

Study on the Safety and Effectiveness of GFH925 and Cetuximab for Patients with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Zhejiang Genfleet Therapeutics Co. Ltd.

Rheumatoid arthritis

Not yet recruiting

Study of Peresolimab for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Peresolimab
  • Sponsor:Eli Lilly & Co.

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Pneumonia

Not yet recruiting

Study on CAL02 and Sodium Chloride for Patients with Severe Community-Acquired Bacterial Pneumonia

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cholesterol
  • Sponsor:Eagle Pharmaceuticals Inc.

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Ischaemic stroke

Not yet recruiting

Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Redasemtide
  • Sponsor:Shionogi B.V.

Sarcoidosis

Not yet recruiting

Study on the Effects of XTMAB-16 and Prednisolone in Patients with Pulmonary Sarcoidosis with or without Other Body Involvement

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Xentria Inc.

Mantle cell lymphoma

Not recruiting

Study on Bendamustine, Rituximab, and Acalabrutinib for Patients with Untreated Mantle Cell Lymphoma

Registered drug
Countries:GreeceGreece
  • Participants:65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Tendon disorder

Not recruiting

Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.